Therapeutic landscape and future direction of metastatic colorectal cancer.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
accepted:
16
12
2022
medline:
1
5
2023
pubmed:
21
1
2023
entrez:
20
1
2023
Statut:
ppublish
Résumé
In the era of targeted therapy based on genomic alterations, the treatment strategy for metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment initiation, determination of tumour genomic status for KRAS and NRAS, BRAF
Identifiants
pubmed: 36670267
doi: 10.1038/s41575-022-00736-1
pii: 10.1038/s41575-022-00736-1
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
306-322Informations de copyright
© 2023. Springer Nature Limited.
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Leporrier, J. et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br. J. Surg. 93, 465–474 (2006).
pubmed: 16523446
doi: 10.1002/bjs.5278
Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065–1075 (2014).
pubmed: 25088940
doi: 10.1016/S1470-2045(14)70330-4
Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317, 2392–2401 (2017).
pubmed: 28632865
pmcid: 5545896
doi: 10.1001/jama.2017.7105
Benson, A. B. et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 19, 329–359 (2021).
pubmed: 33724754
doi: 10.6004/jnccn.2021.0012
Ebi, H. & Bando, H. Precision oncology and the universal health coverage system in Japan. JCO Precis. Oncol. https://doi.org/10.1200/PO.19.00291 (2019).
doi: 10.1200/PO.19.00291
pubmed: 32923862
pmcid: 7446489
Nakamura, Y. & Shitara, K. Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open 5, e000600 (2020).
pubmed: 32830648
pmcid: 7003376
doi: 10.1136/esmoopen-2019-000600
Bando, H., Nakamura, Y., Kotani, D. & Yoshino, Y. Comparing GOZILA and COLOMATE: ongoing umbrella/basket trials examining genetic testing in gastrointestinal malignancies. Oncology 35, 382–389 (2021).
pubmed: 34286943
doi: 10.46883/ONC.2021.3507.0382
Bando, H. et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis. Oncol. 6, e2100535 (2022).
pubmed: 35544728
doi: 10.1200/PO.21.00535
Koopman, M. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100, 266–273 (2009).
pubmed: 19165197
pmcid: 2634718
doi: 10.1038/sj.bjc.6604867
Lochhead, P. et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl Cancer Inst. 105, 1151–1156 (2013).
pubmed: 23878352
pmcid: 3735463
doi: 10.1093/jnci/djt173
Venderbosch, S. et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin. Cancer Res. 20, 5322–5330 (2014).
pubmed: 25139339
pmcid: 4201568
doi: 10.1158/1078-0432.CCR-14-0332
Tol, J., Nagtegaal, I. D. & Punt, C. J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98–99 (2009).
pubmed: 19571295
doi: 10.1056/NEJMc0904160
Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011–2019 (2011).
pubmed: 21502544
doi: 10.1200/JCO.2010.33.5091
Chida, K. et al. The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: a multicenter retrospective observational study. Oncologist 26, 845–853 (2021).
pubmed: 34232546
pmcid: 8488780
doi: 10.1002/onco.13870
Salem, M. E. et al. Landscape of KRAS(G12C), associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers. JCO Precis. Oncol. 6, e2100245 (2022).
pubmed: 35319967
pmcid: 8966967
doi: 10.1200/PO.21.00245
Osterlund, E. et al. KRAS-G12C Mutation in one real-life and three population-based nordic cohorts of metastatic colorectal cancer. Front. Oncol. 12, 826073 (2022).
pubmed: 35251991
pmcid: 8889930
doi: 10.3389/fonc.2022.826073
Latham, A. et al. Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J. Clin. Oncol. https://doi.org/10.1200/jco.18.00283 (2018).
doi: 10.1200/jco.18.00283
pubmed: 30376427
pmcid: 6553803
Fujii, S. et al. International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method. J. Clin. Oncol. 36, 3594 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.3594
Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 738–746 (2016).
pubmed: 27108243
doi: 10.1016/S1470-2045(16)00150-9
Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24, 1395–1402 (2019).
pubmed: 30952821
pmcid: 6795149
doi: 10.1634/theoncologist.2018-0785
Johnson, B. et al. Atypical, non-V600 BRAF mutations as a potential mechanism of resistance to EGFR inhibition in metastatic colorectal cancer. JCO Precis. Oncol. https://doi.org/10.1200/po.19.00102 (2019).
doi: 10.1200/po.19.00102
pubmed: 32923853
pmcid: 7446367
Raghav, K. et al. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget 7, 54627–54631 (2016).
pubmed: 27421137
pmcid: 5342368
doi: 10.18632/oncotarget.10559
Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
pubmed: 26457759
pmcid: 4636487
doi: 10.1038/nm.3967
Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79–92 (2017).
pubmed: 28050011
doi: 10.1038/nrc.2016.126
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02465060 (2015).
Flaherty, K. T. et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). J. Clin. Oncol. https://doi.org/10.1200/jco.19.03010 (2020).
doi: 10.1200/jco.19.03010
pubmed: 33048619
pmcid: 7676882
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT05564377 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05564390 (2022).
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med 23, 703–713 (2017).
pubmed: 28481359
pmcid: 5461196
doi: 10.1038/nm.4333
AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 7, 818–831 (2017).
doi: 10.1158/2159-8290.CD-17-0151
Micheel, C. M. et al. American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: from inception to first data release and beyond — lessons learned and member institutions’ perspectives. JCO Clin. Cancer Inform. 2, https://doi.org/10.1200/CCI.17.00083 (2018).
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://doi.org/10.1200/po.17.00011 (2017).
doi: 10.1200/po.17.00011
pubmed: 28890946
pmcid: 5558263
Johnson, A. et al. Clinical use of precision oncology decision support. JCO Precis. Oncol. https://doi.org/10.1200/po.17.00036 (2017).
doi: 10.1200/po.17.00036
pubmed: 32913978
pmcid: 6016848
Chakravarty, D. et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J. Clin. Oncol. https://doi.org/10.1200/jco.21.02767 (2022).
doi: 10.1200/jco.21.02767
pubmed: 35175857
Nakamura, Y. et al. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: path to the realization of biomarker-guided precision oncology in advanced solid tumors. Cancer Sci. 112, 4425–4432 (2021).
pubmed: 34510657
pmcid: 8586659
doi: 10.1111/cas.15132
Sakamoto, Y. et al. Trajectory for the regulatory approval of a combination of pertuzumab plus trastuzumab for pre-treated HER2-positive metastatic colorectal cancer using real-world data: author contributions. Clin. Colorectal Cancer https://doi.org/10.1016/j.clcc.2022.10.003 (2022).
doi: 10.1016/j.clcc.2022.10.003
pubmed: 36376197
Cervantes, A. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. https://doi.org/10.1016/j.annonc.2022.10.003 (2022).
doi: 10.1016/j.annonc.2022.10.003
pubmed: 36307056
Yoshino, T. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29, 44–70 (2018).
pubmed: 29155929
doi: 10.1093/annonc/mdx738
Morris, V. K. et al. Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol. https://doi.org/10.1200/jco.22.01690 (2022).
doi: 10.1200/jco.22.01690
pubmed: 36351210
Arnold, D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann. Oncol. https://doi.org/10.1093/annonc/mdx175 (2017).
doi: 10.1093/annonc/mdx175
pubmed: 28950290
pmcid: 5834052
Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).
pubmed: 27380959
doi: 10.1093/annonc/mdw235
Engstrom, P. F. et al. NCCN clinical practice guidlines in oncology (NCCN guidelines): colon cancer. J. Natl Compr. Canc. Netw. 7, 778–831 (2022).
doi: 10.6004/jnccn.2009.0056
Yoshino, T. et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial. J. Clin. Oncol. 40, abstr LBA1 (2022).
doi: 10.1200/JCO.2022.40.17_suppl.LBA1
Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H. & Boland, C. R. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol. Hepatol. 7, 262–274 (2022).
pubmed: 35090605
doi: 10.1016/S2468-1253(21)00426-X
Jin, Z. et al. Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): an ARCAD database analysis. J. Clin. Oncol. 40, 3572 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.3572
Zaanan, A. et al. Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials. JAMA Oncol. 4, 379–383 (2018).
pubmed: 28983557
doi: 10.1001/jamaoncol.2017.2899
Taieb, J. et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann. Oncol. 30, 1466–1471 (2019).
pubmed: 31268130
pmcid: 7360150
doi: 10.1093/annonc/mdz208
Cohen, R. et al. Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J. Clin. Oncol. https://doi.org/10.1200/jco.20.01600 (2020).
doi: 10.1200/jco.20.01600
pubmed: 33356421
pmcid: 8189604
André, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).
pubmed: 33264544
doi: 10.1056/NEJMoa2017699
Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659–670 (2022).
pubmed: 35427471
doi: 10.1016/S1470-2045(22)00197-8
Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Clin. Oncol. https://doi.org/10.1200/jco.21.01015 (2021).
doi: 10.1200/jco.21.01015
pubmed: 34637336
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04008030 (2019).
Le, D. T. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38, 11–19 (2020).
pubmed: 31725351
doi: 10.1200/JCO.19.02107
Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).
pubmed: 28734759
pmcid: 6207072
doi: 10.1016/S1470-2045(17)30422-9
Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).
pubmed: 29355075
doi: 10.1200/JCO.2017.76.9901
Cohen, R. et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J. Immunother. Cancer https://doi.org/10.1136/jitc-2020-001499 (2020).
doi: 10.1136/jitc-2020-001499
pubmed: 33148693
pmcid: 7640587
Cohen, R. et al. One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): long-term follow-up of the GERCOR NIPICOL phase II study. J. Clin. Oncol. 40 (Suppl. 4), 13 (2022).
doi: 10.1200/JCO.2022.40.4_suppl.013
Andre, T. et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. J. Clin. Oncol. 39, 9 (2021).
doi: 10.1200/JCO.2021.39.3_suppl.9
Li, J. et al. Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors. J. Clin. Oncol. 40 (Suppl. 4), 1 (2022).
doi: 10.1016/j.ejca.2022.03.027
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02997228 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04041310 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04729322 (2021).
Chen, D. et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS ONE 9, e90607 (2014).
pubmed: 24594804
pmcid: 3940924
doi: 10.1371/journal.pone.0090607
Advani, S. M. et al. Epidemiology and molecular-pathologic characteristics of CpG island methylator phenotype (CIMP) in colorectal cancer. Clin. Colorectal Cancer https://doi.org/10.1016/j.clcc.2020.09.007 (2020).
doi: 10.1016/j.clcc.2020.09.007
pubmed: 33229221
Vedeld, H. M. et al. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int. J. Cancer 141, 967–976 (2017).
pubmed: 28542846
pmcid: 5518206
doi: 10.1002/ijc.30796
Modest, D. P. et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann. Oncol. 27, 1746–1753 (2016).
pubmed: 27358379
pmcid: 4999563
doi: 10.1093/annonc/mdw261
Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur. J. Cancer 51, 587–594 (2015).
pubmed: 25673558
doi: 10.1016/j.ejca.2015.01.054
Loupakis, F. et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur. J. Cancer 50, 57–63 (2014).
pubmed: 24138831
doi: 10.1016/j.ejca.2013.08.024
Loupakis, F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371, 1609–1618 (2014).
pubmed: 25337750
doi: 10.1056/NEJMoa1403108
Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306–1315 (2015).
pubmed: 26338525
doi: 10.1016/S1470-2045(15)00122-9
Cremolini, C. et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J. Clin. Oncol. https://doi.org/10.1200/jco.20.01225 (2020).
doi: 10.1200/jco.20.01225
pubmed: 32816630
Stintzing, S. et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: the phase-II FIRE-4.5 study (AIO KRK-0116). J. Clin. Oncol. 39, 3502–3502 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.3502
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
pubmed: 22281684
doi: 10.1038/nature10868
Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019).
pubmed: 31566309
doi: 10.1056/NEJMoa1908075
Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J. Clin. Oncol. 39, 273–284 (2021).
pubmed: 33503393
pmcid: 8078423
doi: 10.1200/JCO.20.02088
Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J. Clin. Oncol. 39, 285–294 (2021).
pubmed: 33356422
doi: 10.1200/JCO.20.01994
Cutsem, E. V. et al. O-10 ANCHOR CRC: results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer. Ann. Oncol. 32, S222 (2021).
doi: 10.1016/j.annonc.2021.05.014
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04607421 (2020).
Kopetz, S. et al. BREAKWATER: Randomized phase 3 study of encorafenib (enco)+cetuximab (cetux)±chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). J. Clin. Oncol. 39 (Suppl. 15), TPS3619 (2022).
Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473–1480 (2019).
pubmed: 31699882
doi: 10.1126/science.aav4474
Morris, V. K. et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J. Clin. Oncol. 40, 12 (2022).
doi: 10.1200/JCO.2022.40.4_suppl.012
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT05308446 (2022).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT05217446 (2022).
Kotani, H. et al. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene 37, 1775–1787 (2018).
pubmed: 29348459
doi: 10.1038/s41388-017-0035-9
Kotani, D. et al. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open 5, e000624 (2020).
pubmed: 33551068
pmcid: 7046405
doi: 10.1136/esmoopen-2019-000624
UMIN. https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000036377 (2018).
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269–1280 (2014).
pubmed: 25293556
doi: 10.1158/2159-8290.CD-14-0462
Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795–801 (2015).
pubmed: 26030179
pmcid: 4868598
doi: 10.1038/nm.3870
Montagut, C. et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial. JAMA Oncol. 4, e175245 (2018).
pubmed: 29423521
pmcid: 5885274
doi: 10.1001/jamaoncol.2017.5245
Liu, X. et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15, 713 (2015).
pubmed: 26474549
pmcid: 4609167
doi: 10.1186/s12885-015-1701-3
Masuishi, T. et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br. J. Cancer https://doi.org/10.1038/s41416-020-01042-w (2020).
doi: 10.1038/s41416-020-01042-w
pubmed: 32863385
pmcid: 7652864
Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731–736 (2015).
pubmed: 25628445
pmcid: 4374387
doi: 10.1093/annonc/mdv005
Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243–249 (2019).
pubmed: 30462160
doi: 10.1093/annonc/mdy509
Cremolini, C. et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.5080 (2018).
doi: 10.1001/jamaoncol.2018.5080
pubmed: 29450468
pmcid: 6439839
Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE Trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.2915 (2021).
doi: 10.1001/jamaoncol.2021.2915
pubmed: 34382998
pmcid: 8531995
Martinelli, E. et al. Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials. Ann. Oncol. 33, S381–S382 (2022).
doi: 10.1016/j.annonc.2022.04.448
Sartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat. Med. 28, 1612–1618 (2022).
pubmed: 35915157
pmcid: 9386661
doi: 10.1038/s41591-022-01886-0
Nakajima, H. et al. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer 21, 674 (2021).
pubmed: 34098908
pmcid: 8186219
doi: 10.1186/s12885-021-08395-2
Kagawa, Y. et al. Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials. J. Clin. Oncol. https://doi.org/10.1200/JCO.2022.40.16_suppl.3518 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.3518
Moretto, R. et al. Rationale and study design of the PARERE trial: randomized phase II study of panitumumab Re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. Clin. Colorectal Cancer 20, 314–317 (2021).
pubmed: 34364814
doi: 10.1016/j.clcc.2021.07.001
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04787341 (2021).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02934529 (2016).
Fujii, S. et al. International harmonization of provisional diagnostic criteria for ERBB2-amplified metastatic colorectal cancer allowing for screening by next-generation sequencing panel. JCO Precis. Oncol. 4, 6–19 (2020).
pubmed: 35050726
doi: 10.1200/PO.19.00154
Sawada, K. et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 17, 198–205 (2018).
pubmed: 29866615
doi: 10.1016/j.clcc.2018.05.006
Raghav, K. et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis. Oncol. 3, 1–13 (2019).
pubmed: 35100667
Sartore-Bianchi, A. et al. Central nervous system as possible site of relapse in ERBB2-positive metastatic colorectal cancer: long-term results of treatment with trastuzumab and lapatinib. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.0571 (2020).
doi: 10.1001/jamaoncol.2020.0571
pubmed: 32324210
pmcid: 7180725
Richman, S. D. et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 238, 562–570 (2016).
pubmed: 26690310
pmcid: 4785607
doi: 10.1002/path.4679
Ingold Heppner, B. et al. HER2/neu testing in primary colorectal carcinoma. Br. J. Cancer 111, 1977–1984 (2014).
pubmed: 25211663
pmcid: 4229629
doi: 10.1038/bjc.2014.483
Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415–1421 (2019).
pubmed: 31501609
pmcid: 6741444
doi: 10.1038/s41591-019-0561-9
Nakamura, Y. et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat. Med. 27, 1899–1903 (2021).
pubmed: 34764486
pmcid: 8604726
doi: 10.1038/s41591-021-01553-w
Tosi, F. et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin. Colorectal Cancer 19, 256–262.e2 (2020).
pubmed: 32919890
doi: 10.1016/j.clcc.2020.06.009
Meric-Bernstam, F. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 20, 518–530 (2019).
pubmed: 30857956
pmcid: 6781620
doi: 10.1016/S1470-2045(18)30904-5
Gupta, R. et al. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: results from the TAPUR study. J. Clin. Oncol. 38, 132–132 (2020).
doi: 10.1200/JCO.2020.38.4_suppl.132
Strickler, J. et al. Primary analysis of MOUNTAINEER: a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. Ann. Oncol. 33, S375–S376 (2022).
doi: 10.1016/j.annonc.2022.04.440
Siena, S. et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 22, 779–789 (2021).
pubmed: 33961795
doi: 10.1016/S1470-2045(21)00086-3
Siena, S. et al. Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). Ann. Oncol. 32, S530–S582 (2021).
doi: 10.1016/j.annonc.2021.08.908
Raghav, K. P. S. et al. A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613. J. Clin. Oncol. 36 (Suppl. 15), TPS3620 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.TPS3620
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT03365882 (2017).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT05253651 (2022).
Raghav, K. P. S. et al. Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): a randomized, multicenter, phase 2 study (DESTINY-CRC02). J. Clin. Oncol. 39 (Suppl. 15), TPS3620 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.TPS3620
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04744831 (2021).
Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361–375 (2019).
pubmed: 30886395
pmcid: 7295073
doi: 10.1038/s41575-019-0126-x
Riihimaki, M., Hemminki, A., Sundquist, J. & Hemminki, K. Patterns of metastasis in colon and rectal cancer. Sci. Rep. 6, 29765 (2016).
pubmed: 27416752
pmcid: 4945942
doi: 10.1038/srep29765
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. https://doi.org/10.1038/s41591-020-1131-x (2021).
doi: 10.1038/s41591-020-1131-x
pubmed: 34099924
pmcid: 8245201
Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).
pubmed: 32251400
doi: 10.1038/s41591-020-0805-8
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
pubmed: 26028255
pmcid: 4481136
doi: 10.1056/NEJMoa1500596
Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23, 876–887 (2022).
pubmed: 35636444
doi: 10.1016/S1470-2045(22)00274-1
Cremolini, C. et al. FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO. Ann. Oncol. 32, S1294–S1295 (2021).
doi: 10.1016/j.annonc.2021.08.2094
Lenz, H.-J. et al. Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from CheckMate 9×8. J. Clin. Oncol. 40, 8–8 (2022).
doi: 10.1200/JCO.2022.40.4_suppl.008
Schmoll, H. J. et al. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J. Cancer Res. Clin. Oncol. 144, 1197–1204 (2018).
pubmed: 29644408
doi: 10.1007/s00432-018-2632-6
Mettu, N. B. et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial. JAMA Netw. Open 5, e2149040 (2022).
pubmed: 35179586
pmcid: 8857687
doi: 10.1001/jamanetworkopen.2021.49040
Chen, E. X. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 study. JAMA Oncol. 6, 831–838 (2020).
pubmed: 32379280
doi: 10.1001/jamaoncol.2020.0910
Bullock, A. et al. Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann. Oncol. 33, S376 (2022).
doi: 10.1016/j.annonc.2022.04.453
Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849–861 (2019).
pubmed: 31003911
doi: 10.1016/S1470-2045(19)30027-0
Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053–2061 (2020).
pubmed: 32343640
doi: 10.1200/JCO.19.03296
Gomez-Roca, C. et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors — Results from the colorectal cancer cohort. J. Clin. Oncol. 39, 94 (2021).
doi: 10.1200/JCO.2021.39.3_suppl.94
Yoshino, T. et al. Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): phase III LEAP-017 study. Ann. Oncol. 32, S580 (2021).
doi: 10.1016/j.annonc.2021.08.1025
Pietrantonio, F. et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann. Oncol. 25, 404–408 (2014).
pubmed: 24379162
doi: 10.1093/annonc/mdt547
Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017).
pubmed: 29186113
doi: 10.1038/nature24673
Morano, F. et al. Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O(6)-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: The MAYA trial. J. Clin. Oncol. https://doi.org/10.1200/jco.21.02583 (2022).
doi: 10.1200/jco.21.02583
pubmed: 35666229
pmcid: 9426812
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT03519412 (2018).
Crisafulli, G. et al. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. 12, 1656–1675 (2022).
pubmed: 35522273
pmcid: 9394384
doi: 10.1158/2159-8290.CD-21-1434
Monjazeb, A. M. et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer. Clin. Cancer Res. 27, 2470–2480 (2021).
pubmed: 33568343
pmcid: 8102320
doi: 10.1158/1078-0432.CCR-20-4632
Segal, N. H. et al. Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer. Clin. Cancer Res. 27, 2200–2208 (2021).
pubmed: 33504552
pmcid: 8499477
doi: 10.1158/1078-0432.CCR-20-2474
Floudas, C. S. et al. A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 18, e349–e360 (2019).
pubmed: 31351862
pmcid: 6884678
doi: 10.1016/j.clcc.2019.06.004
Nebot-Bral, L. et al. Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur. J. Cancer 84, 290–303 (2017).
pubmed: 28846956
doi: 10.1016/j.ejca.2017.07.026
Yao, J. et al. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Sci. Rep. 9, 15767 (2019).
pubmed: 31673068
pmcid: 6823448
doi: 10.1038/s41598-019-52414-z
Oh, C. R. et al. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. Int. J. Cancer 150, 2038–2045 (2022).
pubmed: 35179785
doi: 10.1002/ijc.33966
Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808–1825 (2020).
pubmed: 33139244
pmcid: 7710563
doi: 10.1158/2159-8290.CD-20-0522
Fancello, L., Gandini, S., Pelicci, P. G. & Mazzarella, L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J. Immunother. Cancer 7, 183 (2019).
pubmed: 31307554
pmcid: 6631597
doi: 10.1186/s40425-019-0647-4
Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).
pubmed: 32919526
doi: 10.1016/S1470-2045(20)30445-9
McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. https://doi.org/10.1016/j.annonc.2021.02.006 (2021).
doi: 10.1016/j.annonc.2021.02.006
pubmed: 34653632
Meiri, E. et al. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): results from the targeted agent and profiling utilization registry (TAPUR) study. J. Clin. Oncol. 38, 133–133 (2020).
doi: 10.1200/JCO.2020.38.4_suppl.133
Rousseau, B. et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N. Engl. J. Med. 384, 1168–1170 (2021).
pubmed: 33761214
pmcid: 8403269
doi: 10.1056/NEJMc2031965
Pages, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).
pubmed: 29754777
doi: 10.1016/S0140-6736(18)30789-X
Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).
pubmed: 34161704
pmcid: 8864540
doi: 10.1056/NEJMoa2105281
Amodio, V. et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.Cd-20-0187 (2020).
doi: 10.1158/2159-8290.Cd-20-0187
pubmed: 32430388
pmcid: 7416460
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04793958 (2021).
Tanaka, N. et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 11, 1913–1922 (2021).
pubmed: 33824136
pmcid: 8338755
doi: 10.1158/2159-8290.CD-21-0365
Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J. Med. Chem. 65, 3123–3133 (2022).
pubmed: 34889605
doi: 10.1021/acs.jmedchem.1c01688
Lenz, H.-J. et al. A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC). J. Clin. Oncol. 40, 100 (2022).
doi: 10.1200/JCO.2022.40.4_suppl.100
Hendifar, A. E. et al. Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC). J. Clin. Oncol. 40, 3579–3579 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.3579
Hendifar, A. et al. Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC). Ann. Oncol. 33, S294 (2022).
doi: 10.1016/j.annonc.2022.04.215
Marchio, C. et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann. Oncol. 30, 1417–1427 (2019).
pubmed: 31268127
doi: 10.1093/annonc/mdz204
Yoshino, T. et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann. Oncol. https://doi.org/10.1016/j.annonc.2020.03.299 (2020).
doi: 10.1016/j.annonc.2020.03.299
pubmed: 33121997
Pietrantonio, F. et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djx089 (2017).
doi: 10.1093/jnci/djx089
pubmed: 29370427
Cocco, E. et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions. Cancer Res. 79, 1047–1053 (2019).
pubmed: 30643016
pmcid: 6420871
doi: 10.1158/0008-5472.CAN-18-3126
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
pubmed: 29466156
pmcid: 5857389
doi: 10.1056/NEJMoa1714448
Hong, D. S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. https://doi.org/10.1016/s1470-2045(19)30856-3 (2020).
doi: 10.1016/s1470-2045(19)30856-3
pubmed: 33129376
pmcid: 7497841
Drilon, A. et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017).
pubmed: 28183697
pmcid: 5380583
doi: 10.1158/2159-8290.CD-16-1237
Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271–282 (2020).
pubmed: 31838007
doi: 10.1016/S1470-2045(19)30691-6
Seligmann, J. F. et al. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. J. Clin. Oncol. 39, 3705–3715 (2021).
pubmed: 34538072
pmcid: 8601321
doi: 10.1200/JCO.21.01435
Strickler, J. H. et al. Cabozantinib and panitumumab for RAS wild-type metastatic colorectal cancer. Oncologist 26, 465–e917 (2021).
pubmed: 33469991
pmcid: 8176979
doi: 10.1002/onco.13678
Pietrantonio, F. et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann. Oncol. 29, 1394–1401 (2018).
pubmed: 29538669
doi: 10.1093/annonc/mdy090
Thein, K. Z., Velcheti, V., Mooers, B. H. M., Wu, J. & Subbiah, V. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 7, 1074–1088 (2021).
pubmed: 34391699
pmcid: 8599646
doi: 10.1016/j.trecan.2021.07.003
Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261–2272 (2022).
pubmed: 35657320
pmcid: 9701133
doi: 10.1056/NEJMoa2200075
Taniguchi, H. et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 112, 2915–2920 (2021).
pubmed: 33931919
pmcid: 8253296
doi: 10.1111/cas.14926
Kann, B. H., Hosny, A. & Aerts, H. Artificial intelligence for clinical oncology. Cancer Cell 39, 916–927 (2021).
pubmed: 33930310
pmcid: 8282694
doi: 10.1016/j.ccell.2021.04.002
Luchini, C., Pea, A. & Scarpa, A. Artificial intelligence in oncology: current applications and future perspectives. Br. J. Cancer https://doi.org/10.1038/s41416-021-01633-1 (2021).
doi: 10.1038/s41416-021-01633-1
pubmed: 34837074
pmcid: 8727615
Kawazoe, A. et al. Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial). Clin. Cancer Res. 26, 5887–5894 (2020).
pubmed: 32694160
doi: 10.1158/1078-0432.CCR-20-1803
Corcoran, R. et al. Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Ann. Oncol. 31, S226–S227 (2020).
doi: 10.1016/j.annonc.2020.04.041
Yaeger, R. et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res. 21, 1313–1320 (2015).
pubmed: 25589621
pmcid: 5546416
doi: 10.1158/1078-0432.CCR-14-2779
Ramanathan, R. K. et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22, 858–865 (2004).
pubmed: 15641483
doi: 10.1081/CNV-200039645
Sartore-Bianchi, A. et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 5, e000911 (2020).
pubmed: 32988996
pmcid: 7523198
doi: 10.1136/esmoopen-2020-000911
Strickler, J. H. et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann. Oncol. 30, v200 (2019).
doi: 10.1093/annonc/mdz246.005
Yuan, Y. et al. Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: preliminary results from a multicenter phase 2 trial. J. Clin. Oncol. 39, e15554 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.e15554
Clark, J. W. et al. Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzamab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy [Abstract]. Proc. Am. Soc. Clin. Oncol. 22, A-3584 (2003).
Bekaii-Saab, T. S. et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol. Cancer Ther. 8, 2983–2991 (2009).
pubmed: 19887543
pmcid: 2996611
doi: 10.1158/1535-7163.MCT-09-0820
Meric-Bernstam, F. et al. Zanidatamab a novel bispecific antibody for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1 dose-escalation and expansion study. Lancet Oncol. 23, 1558–1570 (2022).
pubmed: 36400106
doi: 10.1016/S1470-2045(22)00621-0